$31.27
-1.35 (-4.14%)
Open$32.97
Previous Close$32.62
Day High$33.99
Day Low$31.09
52W High$37.27
52W Low$14.65
Volume—
Avg Volume154.8K
Market Cap471.21M
P/E Ratio—
EPS$-3.16
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
-19.6% upside
Current
$31.27
$31.27
Target
$25.14
$25.14
$17.03
$25.14 avg
$37.02
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 808.7K | 64.19M | 65.56M |
| Net Income | -65,643,442 | 8.40M | 8.13M |
| Profit Margin | -8,123.7% | 13.1% | 12.4% |
| EBITDA | -70,237,992 | 15.55M | 13.35M |
| Free Cash Flow | — | 10.13M | 9.92M |
| Rev Growth | — | +4.7% | +24.1% |
| Debt/Equity | 0.00 | 0.89 | 0.79 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |